age1

Focus

Longevity biotech VC

Services

PR

VISIT THE SITE

age1 is a venture capital firm that funds healthy lifespan extension.

Challenge

As a new early-stage longevity biotech venture firm, age1 needed a high-impact launch to establish awareness and clearly communicate its vision while countering the misconception that longevity science is just for the wealthy.

Approach

Thermal designed and executed a launch strategy that positioned age1 as the next evolution in longevity investing. Key elements included:

    • Narrative development: We crafted a core message emphasizing age1’s scientific rigor, its commitment to expanding healthspan, and its unique model of supporting early-stage biotech startups.
    • Exclusive media outreach: We secured an exclusive with The Wall Street Journal, ensuring that age1’s launch was introduced at the highest level of business and financial reporting.
    • Broad Tier-1 and trade media strategy: Following the WSJ exclusive, we expanded outreach to targeted publications, including Longevity.Technology and Silicon Valley, ensuring a mix of mainstream business, tech, and industry-specific coverage.
    • Spokesperson positioning: We worked closely with age1 leadership to refine messaging for interviews, highlighting the firm’s unique approach and the broader impact of longevity biotech.
    • Rapid response & thought leadership: We identified key misconceptions about longevity investing and proactively placed age1 leadership in conversations about the accessibility and scientific merit of the field, ensuring coverage that extended beyond the initial announcement.

Impact

    • WSJ exclusive: The launch was first announced in an exclusive with The Wall Street Journal, securing immediate credibility with the business and financial audience.
    • Focused coverage: Additional stories appeared in Longevity.Technology, the Mercury News, and Silicon Valley, amplifying the firm’s reach and reinforcing its mission.
    • Clear market positioning: By proactively addressing the “billionaire longevity” narrative, age1’s launch framed the firm as a serious investor in biotech solutions for broader, accessible healthspan extension.
    • Strong industry engagement: The launch generated immediate inbound interest from both startups and investors, solidifying age1’s role as a leader in early-stage longevity biotech.

    age1 entered the market with a strong foundation, positioned not just as a venture firm but as a key player in shaping the future of longevity science. Thermal’s strategic storytelling ensured the launch resonated with the right audiences, helping age1 establish momentum and credibility from day one.

“We feel strongly that a next-generation fund with more founder resources is required to accelerate the longevity paradigm shift we are on the precipice of. age1 will back ambitious and pragmatic founders building companies to give people the agency to choose how long they live, in good health.”

Alex Colville – General Partner of age1

 

This is a unique website which will require a more modern browser to work!

Please upgrade today!